Skip to content

Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®

Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01901458
Acronym
optiMaL
Enrollment
50
Registered
2013-07-17
Start date
2014-03-31
Completion date
2014-11-30
Last updated
2015-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Granulocyte Colony-stimulating Factor (G-CSF) Mobilized, Healthy Allogeneic Donors

Keywords

apheresis, peripheral blood progenitor cells, peripheral blood stem cells

Brief summary

The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system. The study will assess the reduction of apheresis time to obtain the required amount of hematopoietic progenitor cells.

Detailed description

Peripheral blood progenitor cells (PBPC) collected by apheresis are the most common stem cell source for allogeneic hematopoietic stem cell transplantation. Recently, Terumo BCT introduced a novel automated apheresis system for PBPC collection. The Spectra Optia® apheresis system uses the Spectra Optia® Collection set and the MNC software for PBPC collection. This system combines continuous centrifugation (high g) and subsequent cellular collection into an elutriation chamber, where the platelets are elutriated from mononuclear cells. An optical sensor detects when red blood cells begin to be elutriated and subsequently triggers the collection of the buffy coat into the product bag by flushing the chamber with donor plasma. Thus PBPCs are harvested intermittently. In contrast, the same apheresis systems in combination with the Spectra Optia® IDL set and the WBC-D software, which has been designed to perform leukodepletion procedures, permits continuous PBPC centrifugation (low g) and harvesting. The investigators hypothesis is that the use of the IDL set with manual adaption of the WBC-D-software allows a more efficient PBPC collection compared to the collection set which is recommended for PBPC collection. The apheresis time to collect the same amount of target cells dependent on the donors peripheral blood count will be shortened. In addition, the investigators want to compare both systems with respect to the cellular composition of the apheresis product and the donors platelet loss and coagulation parameters during apheresis.

Interventions

DEVICESpectra Optia® IDL-Set

Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator

DEVICESpectra Optia® Collection Set

Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator

Sponsors

Terumo BCT
CollaboratorINDUSTRY
Chugai Pharma USA
CollaboratorINDUSTRY
Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* ability to give informed consent to participate in the study * meets german eligibility criteria (ZKRD-Standards, hemotherapy guidelines) for peripheral blood stem cell donation * has been treated with G-CSF 10 µg per kg per day for 5 days

Exclusion criteria

* demand of concurrent plasma

Design outcomes

Primary

MeasureTime frameDescription
Throughput (TP)Day 1Efficiency of peripheral blood progenitor cell collection measured as throughput (collection rate (CR) per minute)

Secondary

MeasureTime frameDescription
Collection efficiency (CE) 1Day 1Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell counts pre and post apheresis)
CE2Day 1Percentage of harvested cells per processed cells (calculated by use of the peripheral blood progenitor cell count pre apheresis)
Product T cellsDay 1% T cells as a definition of the cellular composition of the product
Product NK cellsDay 1% NK cells as a definition of the cellular composition of the product
CR per total blood volume (TBV)Day 1Efficiency of peripheral blood progenitor cell collection measured as CR per TBV

Other

MeasureTime frameDescription
Peripheral blood CD62P before and after apheresisday 1Percentage of CD62P positive platelets as a measure of platelet activation during apheresis
kinetics of peripheral blood cell countday 1, day30measurement of the peripheral blood cell count before and after apheresis and 30 days after collection
levels of electrolytes before and after apheresisday 1, day 30sodium, potassium and calcium are measured before and after apherese and 30 days after collection

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026